ABSTRACT
Curcumin was loaded into different polysaccharide nanoparticles chitosan, alginate and starch, using the desolvation method. Curcumin-loaded nanoparticles exhibited enhanced solubility in aqueous solutions comparing with free curcumin. Effects of formulation parameters such as curcumin concentration and different volumes of ethanolic solution were affected the particle size and loading efficiency. Under optimum conditions, curcumin-loaded chitosan, starch and alginate nanoparticles with mean particles sizes of 66.3, 61.1 and 78.8nm, and maximum loading efficiencies of 11.9%, 14.3% and 13.35% were achieved, respectively. Additionally, the minimum inhibitory concentration for chitosan, starch and alginate nanoparticles against the microorganism, Streptococcus mutans, were 0.114, 0.204 and 0.204mg/mL, respectively. Curcumin was observed to release from nanoparticles under physiological pH over a period of 96h. The effect of curcumin-loaded nanoparticles on S. mutans biofilms was assessed on dental models. According to the results, curcumin-loaded chitosan nanoparticles hold promises for being used in dental decay fighting products.
Subject(s)
Biofilms/growth & development , Curcumin , Nanoparticles/chemistry , Polysaccharides, Bacterial/chemistry , Streptococcus mutans , Curcumin/chemistry , Curcumin/pharmacokinetics , Curcumin/pharmacology , Delayed-Action Preparations/chemistry , Delayed-Action Preparations/pharmacokinetics , Delayed-Action Preparations/pharmacology , Streptococcus mutans/chemistry , Streptococcus mutans/physiologyABSTRACT
Pharmacological treatments of polycystic ovary syndrome (PCOS) have side effects. We compared the efficacy and safety of the aerial parts of wood botany (AWB) with those of Medroxyprogesterone acetate (MPA) in the management of abnormal uterine bleeding (AUB) due to PCOS. We conducted a randomized clinical trial of 66 women aged 15-45 years, with AUB. Participants were randomly assigned to either cyclical 10-mg BD MPA for three cycles or 5 g ABW TDS for three months. Clinical symptoms and paraclinical parameters were recorded before and 3 months after initiation of the treatment. Comparisons were made using generalized linear models. Age-adjusted prevalence rate of different patterns of AUB, decreased from 2.7 (95%CIs: 0.6-48.0) to 1.1 (95%CIs: 0.1-18.3) for patients taking MPA, and from 2.5 (95% CIs: 0.2-40.2) to 0.7 (95%CIs: 0.0-12.1). Decrease in prevalence rate was similar across two arms of the study (P value = 0.248). Adverse effects were observed less frequently (24.2%) among participants on MPA than among those on AWB (45.5%). The multivariate-adjusted odds for developing adverse reaction of MPA was 0.40 (95%CIs: 0.14-1.19, P value = 0.099) time odds of AWB. In conclusion, AWB may be used as an alternative for MPA in the treatment of AUB caused by PCOS.